Arialys Therapeutics

News

April 2, 2025

Arialys Presents Two Abstracts at AAN 2025

Arialys Therapeutics will be presenting two abstracts and participating in a panel at the 𝗔𝗺𝗲𝗿𝗶𝗰𝗮𝗻 𝗔𝗰𝗮𝗱𝗲𝗺𝘆 𝗼𝗳 𝗡𝗲𝘂𝗿𝗼𝗹𝗼𝗴𝘆 (𝗔𝗔𝗡) 𝟮𝟬𝟮𝟱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 in San Diego. Our presentations will highlight new data supporting the development of ART5803, our clinical-stage antibody for anti-NMDA receptor neuropsychiatric diseases, as well as a novel assay for detecting anti-NMDAR autoantibodies.

‍

🔹 Oral Presentation | April 6, 4:06–4:18 p.m. PT

𝗜𝗡𝗗-𝗘𝗻𝗮𝗯𝗹𝗶𝗻𝗴 𝗦𝗮𝗳𝗲𝘁𝘆 𝗦𝘁𝘂𝗱𝗶𝗲𝘀 𝗳𝗼𝗿 𝗔𝗥𝗧𝟱𝟴𝟬𝟯, 𝗮 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝗦𝘁𝗮𝗴𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗢𝗻𝗲-𝗔𝗿𝗺𝗲𝗱 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝘁𝗼 𝗧𝗿𝗲𝗮𝘁 𝗔𝗻𝘁𝗶-𝗡𝗠𝗗𝗔 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗘𝗻𝗰𝗲𝗽𝗵𝗮𝗹𝗶𝘁𝗶𝘀

🔗 https://www.aan.com/msa/Public/Events/AbstractDetails/58546

‍

🔹 Poster Presentation | April 5, 11:45 a.m.–12:45 p.m. PT

𝗡𝗼𝘃𝗲𝗹 𝗦𝗲𝗺𝗶-𝗤𝘂𝗮𝗻𝘁𝗶𝘁𝗮𝘁𝗶𝘃𝗲 𝗛𝗶𝗴𝗵 𝗦𝗲𝗻𝘀𝗶𝘁𝗶𝘃𝗶𝘁𝘆 𝗘𝗟𝗜𝗦𝗔 𝗳𝗼𝗿 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗻𝗴 𝗔𝗻𝘁𝗶-𝗡𝗠𝗗𝗔 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗔𝘂𝘁𝗼𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗶𝗻 𝗦𝗲𝗿𝘂𝗺 𝗮𝗻𝗱 𝗖𝗦𝗙

🔗 https://www.aan.com/msa/Public/Events/AbstractDetails/58728

‍

🔹 Panel Discussion | April 6, 1:00–1:30 p.m. PT

𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆

🔗 https://www.aan.com/msa/Public/Events/Details/20486

Sign up for news updates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

News

Sign up for news updates

Follow us